Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Glaucoma Clinical Trial

Official title:

A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04577300
• Other study ID #: 56950
• Status: Recruiting
• Phase: Phase 2
• Start date: May 15, 2021
• Est. completion date: December 15, 2024

Study information

• Verified date: November 2023
• Source: Stanford University
• Contact: Mariana Nunez, MD
• Phone: 6504977846
• Email: mnunez[@]stanford.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

Description:

A randomized, sham controlled, masked trial of up to 30 eyes will be recruited into the study. Participants with a qualifying study eye will be randomized after screening and baseline evaluations to receive 2 NT-501 ECT implants in the study eye (20 eyes), 1 NT-501 ECT implant (5 eyes) or a sham surgery (control arm; 5 eyes). No explant will be required. An examination for safety will occur one day and one week following implant and periodically thereafter for 24 months post-implant. Patients in the control arm may be offered 2 NT-501 ECT implants after the 12-month post-operative follow-up visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 15, 2024
• Est. primary completion date: August 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participant must be medically able to undergo the testing required in the schedule of events (SOE).

2. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) of -3 to -20 dB on Humphrey Visual Field 24-2 testing and two visual field tests of adequate quality with a maximum VFI variability of ± 10%

3. Residual visual field preservation including best-corrected visual acuity (BCVA) better than 20/200 in either eye.

4. Participant's eye pressure must be clinically stable, with IOP <21.

5. If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, a randomization procedure will assign one eye to the study.

6. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

7. Females of childbearing potential must agree to use an effective form of birth control.

8. Participant must be determined by the presurgical anesthesia or medical team to be fit for ophthalmic surgery for the NT-501 ECT implant insertion.

Exclusion Criteria:

1. Participant is unable to comply with study procedures or followup visits.

2. Participant has other optic nerve or retinal degenerative disease causing vision loss, irrespective of whether it is currently treated or untreated.

3. Participant is likely to be offered glaucoma surgery in the study eye within 6 months of screening.

4. Participant has cataract-associated vision loss to less than 20/40.

5. Participant has a history of ocular herpes zoster.

6. Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.

7. Participant has evidence of corneal opacification or lack of optical clarity.

8. Participant has uveitis or other ocular inflammatory disease.

9. Participant is receiving systemic steroids or other immunosuppressive medications.

10. Participant has diabetic macular edema and/or diabetic retinopathy.

11. Participant has myopic degeneration.

12. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.

13. Participant is pregnant or lactating.

14. Participant is on chemotherapy.

15. Participant has a history of malignancy other than basal cell carcinoma, unless it was treated successfully 2 years prior to inclusion in the trial.

16. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.

17. Any intraocular surgery of the study eye within 12 weeks prior to the screening visit

18. History of use of drugs with known retinal toxicity, at retinotoxic doses.

19. Patient has a history of multiple sclerosis.

Related Conditions & MeSH terms

• Glaucoma

Intervention

Drug:
• NT-501
Implant of Neurotech NT-501 device(s)

Other:
• Sham comparator
Sham implantation

Locations

Country	Name	City	State
United States	Byers Eye Institute at Stanford University	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Field MD at 12 Months	Change from baseline in visual field through 12 months as assessed by Mean Deviation (MD).	12 months
Secondary	Visual Field Index at 12 months	Change from baseline in visual field through 12 months as assessed by Visual Field Index (VFI).	12 months
Secondary	Visual Field PLR at 12 months	Change from baseline in visual field pointwise linear regression (PLR) through 12 months.	12 months